The global rare disease drug market is expected to touch $242 billion by 2024 with a Compound annual growth rate (CAGR) of 12.3 per cent between 2019-2024. Globally, the definition of rare disease (RD) is at nascent stage although it is evolving constantly. It is assumed that there are approximately 8,000 different types of RDs, with more being discovered each day. Particularly in India, nearly 450 RDs have been enlisted. Due to its poor diagnosis mechanism, low prevalence and limited treatment options, often it is addressed as an 'orphan' disease.
Rare diseases in India
The Ministry of Health and Family Welfare, Government of India announced that so far only about 450 rare diseases have been recorded in India from tertiary care hospitals. The most common rare diseases include haemophilia, thalassemia, sickle cell anemia, primary immunodeficiency in children, auto-immune diseases, lysosomal storage disorders such as Pompe disease, Hirschsprung disease, Gaucher’s disease, cystic fibrosis, hemangiomas and certain forms of muscular dystrophies.
Dr Prashanth L K, Consultant Movement Disorders Specialist, Vikram Hospital informs, “ According to the definition, a rare movement disorder is one whose prevalence is less than 50 per 100,000 population. India constitutes 1/5th of this global scenario. Many of these disorders require dedicated healthcare services and some of them have dramatic medical care. Because of the rarity of these disorders, most of them are usually misdiagnosed and do not get proper interventions.”
هذه القصة مأخوذة من طبعة January 16-31, 2020 من Express Pharma.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك ? تسجيل الدخول
هذه القصة مأخوذة من طبعة January 16-31, 2020 من Express Pharma.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك? تسجيل الدخول
Powerful Process Control with IND500x Weighing Indicators
Ensuring consistent quality in hazardous environments, particularly in Ex-Areas (Zone 1/21, Division 1), is a critical aspect of industrial operations. The IND500x weighing indicators from METTLER TOLEDO provide a robust solution for these challenging settings, offering optimized safety and productivity.
Ensuring clean room integrity with prime clean reset high-speed doors
Prime Clean Reset high-speed doors ensure airtight seals, minimising air permeability and contamination in clean rooms. Designed for sensitive environments, they enhance operational efficiency and meet rigorous regulatory standards, making them ideal for pharmaceutical and biotech industries
Complete environmental monitoring solution - testo Saveris Pharma
There are several critical applications in the industry like research and development that demand for continuous & reliable monitoring of important environmental parameters.
Adaptive Manufacturing:-The new flexibility in medical device assembly
Unlike traditional, rigid production lines, B&R's adaptive machines seamlessly adjust to the requirements of each device, dynamically adapting to each unique process
Reshaping pharma safety with active packaging innovations
CILICANT is revolutionising active packaging with solutions tailored for the most sensitive formulations. Meet the innovators driving stability, safety, and impurity control in pharma packaging at CPhI India
UNLOCKING GROWTH FRONTIERS
Vadodara Pharma Summit 2024 brought together industry leaders and experts to highlight the city's pivotal role in India's pharma landscape and explore collaborative strategies to strengthen India's pharma innovation ecosystem
Optimising cloud provisioning for pharmaceutical compliance and operational excellence
Suresh Perikala, Senior Engineering Lead - DevOps and Cloud Engineering Practice, Altimetrik
Accelerating pharma's sustainability efforts
Avinaw Prasad, Director, Climate Change & Sustainability, Deloitte India explains why integrating sustainability into the core pharma business strategy is essential for long-term success, analyses key focus areas and policy pushes which can incentivise companies to further evolve on the sustainability path
Drug Repurposing: Unlocking access to rare solutions
Drug repurposing, a quick, cost-effective path to deliver existing treatments to patients, can serve to expedite and expand healthcare access for patients with rare diseases
Optimising spend, maximising growth
Express Pharma, in partnership with IPA and CHEMEXCIL, powered by SAP, recently organised a thought leadership conclave on 'Reimagining spend management and supply chain' where cross functional experts explored strategies to drive value through supply chain transformation